EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Chemours Co (CC) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Chemours Co $8.90, price $14.74, upside -39.6%, quality 36 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Basic Materials · US · ISIN US1638511089

CC Chemours Co logo Some data Sep 24, 2026

Chemours Co

CC · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $8.90 · Strongly overvalued (−40%)
!Quality 36/100
!Weak Growth (revenue 5y +3.2 %/yr)
!Loss-making · -7.0% net margin (TTM)
!High debt · generates free cash flow
·2.37% dividend yield
!Trails peers (3/14)
!Narrow moat 18/100
!Insider activity 40/100
!Evidence only medium, so the estimate is less certain
!Weak on future: 5 out of 100
Watch Chemours Co for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$38.99 $9.20 Fair Value $8.90 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $9.20 – $38.99 · fair‑value band $8.24 – $8.90 · the $14.74 price screens above the $8.90 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Chemours Co in your weekly email

Every Wednesday you see whether Chemours Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. The company operates through three segments: Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials.

Show more

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. The company operates through three segments: Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials. The Thermal & Specialized Solutions segment provides refrigerants, thermal management solutions, propellants, foam blowing agents, and specialty solvents under the Freon and Opteon brand names. The Titanium Technologies segment offers TiO2 pigment, a white pigment that delivers whiteness, brightness, opacity, durability, efficiency, and protection in applications, including architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard for use in packaging under the Ti-Pure brand name. The Advanced Performance Materials segment products portfolio includes various specialty product solutions, membranes, industrial resins, additives, films, and coatings for consumer electronics, semiconductors, digital communications, transportation, energy, oil and gas, and medical markets under the Teflon, Viton, Krytox, and Nafion brand names. It sells its products through direct and indirect channels, as well as through a network of resellers, third-party sales agents, and distributors. The Chemours Company was incorporated in 2014 and is headquartered in Wilmington, Delaware.

Stock analysis

Chemours Co (CC) currently trades at $14.74, while our model-based Fair Value estimate is $8.90, implying the stock looks roughly 65.6% overvalued today.

Show more

Valuation

Bull case: the Dividend Discount group reads highest at a median of $4.96 per share, and 0 of the 3 models we run sit above the $14.74 price.

Bear case: the Asset-Based group reads lowest at $1.11, and 3 of the 3 models stay below the price. Evidence for this calculation is medium.

Scenario range: $8.24 (bear) to $8.90 (bull), the price of $14.74 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Basic Materials sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Chemours Co reported revenue of $5.8B in FY2025 versus $6.3B in FY2021, a compound −2.2%/yr. Reported net income was −$386M in FY2025.

Key figures

Market cap $2.6B · P/S ratio 0.45 · EPS (TTM) $−2.73 · Dividend yield 2.4% · Net margin −6.6% · Return on equity −103% · Return on assets (EBIT) 4.7% · Operating margin 3.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 47% below its 52-week high and 42% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Basic Materials peers we cover trades at −48% fair-value upside, at −40%, CC screens cheaper than that median.

Fair Value models

Bear $8.24 Fair Value $8.90 Bull $8.90
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF n/a n/a $10.03 77
Growth DCF n/a n/a $9.32 75
5Y EBITDA Exit n/a n/a $7.91 72
All 8 models by family
DCF Models
FCF DCF n/a n/a $10.03 77
5Y EBITDA Exit n/a n/a $7.91 72
10Y EBITDA Exit n/a n/a $2.01 65
Dividend Discount
Gordon GGM $4.56 $4.96 $5.58 69
DDM Multi-Stage $4.56 $5.63 $7.09 67
Multiples
EV/EBITDA n/a n/a $5.06 62
Asset-Based
NCAV (Graham) $0.8300 $1.11 $1.66 54
Growth DCF
Growth DCF n/a n/a $9.32 75

Open the full fair value analysis →

Notify me when CC reaches fair value

Put CC on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 36/100

Of which business quality 34 · Market factors (momentum, volatility) 16

Profitability 16
Margins and returns on capital today
Quality Growth 17
Are margins and returns improving?
Cashflow 16
Earnings quality: real cash, not paper profit
Fin. Strength 12
Balance sheet, leverage, solvency risk
Investment 97
Disciplined investing over empire-building
Low Volatility 15
Calm price path (market factor)
Momentum 13
Price trend over the last 3–12 months (market factor)
52W Momentum 23
Distance to the 52-week high (market factor)
Net Issuance 88
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+0.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.2%
Start year 2020 (pandemic). Over 10 years: +0.2% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
9.0% (2020) → −0.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+46.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +43.3% a year for the price and +2.3% for the forecasts.
Forecast 2026 (sales)+4.1%
Forecast 2027 (sales)+5.6%
Projected 2028 (sales)+5.2%
Projected 2029 (sales)+4.7%
Projected 2030 (sales)+4.3%

CC screens 66% overvalued. Compare with Linde plc →

Compare Chemours Co with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 706 stocks

Beats the industry median on 3/13 measures
Overall it trails its industry peers.
Valuation
Quality Score 36 · Bottom 25%
Fair Value upside −41% · Below median
Profitability
Return on assets 2% · Below median
Net margin (TTM) −7% · Bottom 25%
Operating margin (TTM) 3% · Below median
Growth and dividend
Revenue growth 1% · Below median
Dividend yield (TTM) 2.4% · Above median
Balance sheet
Debt / equity 16.40× · Highest 25%

Valuation Multiplesvs Specialty Chemicals median · lower = cheaper

P/B 10.42× · Priciest 25%
P/S (TTM) 0.45× · Cheapest 25%
P/FCF 51.1× · Priciest 25%
EV/EBITDA 10.4× · Cheaper than median
PEG 1.60× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)5 · sector 21
PAST (return on equity)0 · sector 23
HEALTH (low debt)0 · sector 95
DIVIDEND (yield)47 · sector 29

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Linde plc LIN $464.91 $441.28 −5%
The Sherwin-Williams Company SHW $328.35 $148.97 −55%
Ecolab Inc ECL $276.22 $96.18 −65%
Air Products and Chemicals, Inc APD $287.86 $122.14 −58%
Givaudan SA GIVN CHF 3,464 CHF 1,523 −56%
Wanhua Chemical Group 600309 ¥70.66 ¥68.03 −4%
Sika AG SIKA CHF 188.90 CHF 98.89 −48%
Asian Paints Limited ASIANPAINT ₹2,449 ₹1,479 −40%
PPG Industries, Inc PPG $107.77 $77.06 −28%
DSM-Firmenich AG DSFIR CHF 91.50 CHF 29.27 −68%

Explore undervalued stocks

More undervalued Basic Materials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Chemours Co · Fair Value
$8.90 −66%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Chemours Co Fair Value". https://www.fairvalue-calculator.com/stock/CC

Frequently asked questions

Is Chemours Co (CC) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $8.90 versus a price of $14.74, about −40% upside (overvalued).
What is the fair value of CC?
Our model-based fair value for Chemours Co is $8.90 (as of Sep 24, 2026), built from audited fundamentals. The current price: $14.74.
What is the quality score of CC?
Chemours Co has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Chemours Co (CC)?
Our model-based price target is the fair value of $8.90 (as of Sep 24, 2026) from 8 valuation models. Cautious scenario $8.24, optimistic scenario $8.90. It is a calculation from audited fundamentals, not an analyst target.
What is the Chemours Co stock forecast for 2026?
Our models put fair value at $8.90, about −40% upside versus a price of $14.74 (overvalued). Cautious scenario $8.24, optimistic scenario $8.90. The calculation is refreshed regularly with new filings.
What is the revenue of Chemours Co (CC)?
Chemours Co reported trailing-twelve-month revenue of about $5.8B (latest available figure, as of Sep 24, 2026).
Does Chemours Co pay a dividend?
Chemours Co currently shows a dividend yield of about 2.37% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Chemours Co (CC)?
For today's price to be fair in a discounted-cash-flow model, Chemours Co would have to grow free cash flow by +46.7 % per year for five years (discount rate 10.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +3.2 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of CC use?
Our models discount Chemours Co at 10.7 %: a base by market capitalisation (mid), damped by beta 1.40, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Chemours Co that is +46.7 % per year a year over ten years, using the same discount rate (10.7 %) and the same formula as our fair value.
How much growth has Chemours Co (CC) delivered so far?
Over the past 5 years revenue at Chemours Co grew +3.2 % a year. The price currently implies +46.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Chemours Co (CC) growing?
The median revenue growth in the sector is +3.3 % a year. That is the yardstick for the growth priced into Chemours Co (+46.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Chemours Co (CC)?
The free-cash-flow yield on the price is 2.30 %: that much free cash flow Chemours Co produces per unit of market value. When it exceeds the discount rate of our models (10.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Chemours Co (CC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Chemours Co it is $8.90 per share (as of Sep 24, 2026), against a price of $14.74. It is the blended result of 8 valuation models (cash flow, earnings, asset, dividend).
Is Chemours Co stock overvalued or undervalued in 2026?
As of Sep 24, 2026, CC trades above its calculated fair value: price $14.74, fair value $8.90, a gap of about −40% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CC?
No. The price is what the market pays today ($14.74); the fair value is what the company's own numbers justify ($8.90). For Chemours Co the two are $5.84 per share apart. That gap is exactly why we show both numbers side by side.
How much is Chemours Co worth?
The market values Chemours Co at about $2.6B (market capitalisation, as of Sep 24, 2026). Per share that is $14.74; our models calculate a fair value of $8.90 per share.
What do the bullish and bearish scenarios say about CC?
Our models span a range for Chemours Co: cautious scenario $8.24, base $8.90, optimistic $8.90 per share (as of Sep 24, 2026, price $14.74). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of CC?
The PEG ratio of Chemours Co is 1.60 (P/E divided by earnings growth, as of Sep 24, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Chemours Co (CC)?
Balance-sheet figures for Chemours Co (as of Sep 24, 2026): return on equity −103.0%, debt of 16.40 per unit of equity. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is CC from its 52-week high?
Chemours Co trades at $14.74, about 47% below its 52-week high of $27.84 and 42% above the low of $10.39 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $8.90 is for.
Which stocks are comparable to Chemours Co?
From the same area (Basic Materials) we also value Linde plc, The Sherwin-Williams Company, Ecolab Inc, Air Products and Chemicals, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Chemours Co stock attractive at the current price?
The data as of Sep 24, 2026: price $14.74, calculated fair value $8.90 (−40%), Quality Score 36/100, from 8 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CC calculated?
We run Chemours Co through 8 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $8.90, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Chemours Co itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Chemours Co (CC)?
The closing price on Sep 23, 2026 was $14.74. Our model-based fair value is $8.90, about −40% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Chemours Co right now?
The price sits above even our optimistic bull case ($8.90). The favourable scenario is already priced in. Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts. The models converge in a tight band ($8.24 to $8.90), unusually little disagreement for a valuation.

Key figures of Chemours Co

How large is the market capitalisation of Chemours Co (CC)?
The market capitalisation of Chemours Co is $2.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Chemours Co (CC)?
The price-to-sales ratio of Chemours Co is 0.45 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Chemours Co (CC)?
Earnings per share at Chemours Co are $−2.73. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Chemours Co (CC)?
The dividend yield of Chemours Co is 2.4%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Chemours Co (CC)?
The net margin of Chemours Co is −6.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Chemours Co (CC)?
The return on equity (ROE) of Chemours Co is −103% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Chemours Co (CC)?
On an EBIT basis the return on assets of Chemours Co is 4.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Chemours Co (CC)?
The operating margin of Chemours Co is 3.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Chemours Co (CC)?
Revenue at Chemours Co is growing +1.0% versus a year earlier (3y avg −5.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Chemours Co (CC)?
Earnings per share at Chemours Co are growing −64.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Chemours Co (CC) carry?
The net debt of Chemours Co is $3.9B (fiscal year 2025, ≈ 76.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Chemours Co in the live analysis

One click puts Chemours Co on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.